Trials / Not Yet Recruiting
Not Yet RecruitingNCT07049978
Long-term Effect of Dupilumab in N-ERD
Long-term Effect of Dupilumab on Acetylsalicylic Acid (ASA) Intolerance and Its Mechanisms in Patients With Non-steroidal Anti-inflammatory Drug-exacerbated Respiratory Disease (N-ERD)
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- Medical University of Vienna · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective observational study investigates the long-term effects of Dupilumab in patients with NSAID-exacerbated respiratory disease (N-ERD). The study assesses changes in ASA tolerance, clinical parameters, inflammatory biomarkers, quality of life, and nasal microbiome during ongoing treatment with Dupilumab. All participants are receiving Dupilumab as part of standard clinical care.
Conditions
- NSAID-Induced Asthma
- NSAIDs Hypersensitivity
- Chronic Rhinosinusitis (CRS)
- Asthma Bronchiale
- Nasal Polyposis
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Observational follow-up of standard Dupilumab treatment | Patients undergoing Dupilumab treatment for N-ERD will be observed after three to four years of treatment to assess long term changes in ASA tolerance, clinical parameters, inflammatory biomarkers, quality of life, and nasal microbiome during ongoing treatment with Dupilumab. All participants are receiving Dupilumab as part of standard clinical care. |
Timeline
- Start date
- 2025-07-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
- First posted
- 2025-07-03
- Last updated
- 2025-07-08
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT07049978. Inclusion in this directory is not an endorsement.